Rifaximin on intestinally‐related pathologic changes in sickle cell disease

Dutta, Dibyendu; Li, Kelvin; Methé, Barbara A.; Lim, Seah H.

doi:10.1002/ajh.25722

Cited by 14 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a shift towards increased abundance of Bacteroides and Akkermansia in the intestine. Rifaximin improved intestinal permeability, decreased intestinal injury, and reduced the translocation of LPS [120]. These improvements in the intestinal pathophysiology reversed upon discontinuation of the rifaximin [121].…”

Section: Semi-selective Modification Of Intestinal Microbiome Using Amentioning

confidence: 87%

Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions

Dutta

Lim

2020

Biomark Res

Self Cite

View full text Add to dashboard Cite

Gut microbiota composition influences the balance between human health and disease. Increasing evidence suggests the involvement of microbial factors in regulating cancer development, progression, and therapeutic response. Distinct microbial species have been implicated in modulating gut environment and architecture that affects cancer therapy outcomes. While some microbial species offer enhanced cancer therapy response, others diminish cancer treatment efficacy. In addition, use of antibiotics, often to minimize infection risks in cancer, causes intestinal dysbiosis and proves detrimental. In this review we discuss the role of gut microbiota in cancer development and therapy. We also provide insights into future strategies to manipulate the microbiome and gut epithelial barrier to augment therapeutic responses while minimizing toxicity or infection risks.

show abstract

Section: Semi-selective Modification Of Intestinal Microbiome Using Amentioning

confidence: 87%

Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions

Dutta

Lim

2020

Biomark Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…SCD patients show intestinal dysbiosis [ 26 ]. Antibiotic administration to SCD patients [ 27 ] and mice [ 24 ] both led to drops in circulating aged neutrophils (CANs), through a combination of reduction in the intestinal microbial load and alteration in the microbial compositions [ 28 ]. In SCD patients, there were also associated drops in the serum CD62L [ 28 ], indicating a downregulation of the inflammatory processes when the intestinal microbial load and/or composition is altered.…”

Section: Introductionmentioning

confidence: 99%

“…Based on a small study showing that the antibiotic rifaximin reduced the frequency of VOC, rifaximin [ 27 ] may also be tried during VOC episodes to reduce the intestinal microbial load and prevent sVOC. Rifaximin use in the preventive setting reduce the number of CANs and serum LPS [ 28 ]. Antibiotic use may also downregulate the VOC due to microbiota-mediated expansion of CANs [ 47 ] induced by the stress due with pain during VOC.…”

Section: Introductionmentioning

confidence: 99%

Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events

et al. 2021

Self Cite

View full text Add to dashboard Cite

Painful vaso-occlusive crisis (VOC) remains the most common reason for presenting to the Emergency Department and hospitalization in patients with sickle cell disease (SCD). Although two new agents have been approved by the Food and Drug Administration for treating SCD, they both target to reduce the frequency of VOC. Results from studies investigating various approaches to treat and shorten VOC have so far been generally disappointing. In this paper, we will summarize the complex pathophysiology and downstream events of VOC and discuss the likely reasons for the disappointing results using monotherapy. We will put forward the rationale for exploring some of the currently available agents to either protect erythrocytes un-involved in the hemoglobin polymerization process from sickling induced by the secondary events, or a multipronged combination approach that targets the complex downstream pathways of VOC.

show abstract

“…This has been associated with intestinal dysbiosis that is characterized by a lower abundance of Alistipes and Pseudobutyrivirio [80]. Manipulation of the intestinal microbial community with the antibiotic rifaximin that led to an increased abundance of Akkermansia [81] was associated with a reduced frequency of painful vasoocclusive crisis [82], creating an opportunity to use FMT from non-sickle cell donors with or without ex vivo enrichment with Akkermansia or Alistipes, which may be explored in the future to change the disease course in SCD.…”

Section: Ongoing Fmt Studies In Patients With Hematologic and Oncolog...mentioning

confidence: 99%

Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice

Zerdan

Niforatos

Nasr

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Understanding of the importance of the normal intestinal microbial community in regulating microbial homeostasis, host metabolism, adaptive immune responses, and gut barrier functions has opened up the possibility of manipulating the microbial composition to modulate the activity of various intestinal and systemic diseases using fecal microbiota transplant (FMT). It is therefore not surprising that use of FMT, especially for treating relapsed/refractory Clostridioides difficile infections (CDI), has increased over the last decade. Due to the complexity associated with and treatment for these diseases, patients with hematologic and oncologic diseases are particularly susceptible to complications related to altered intestinal microbial composition. Therefore, they are an ideal population for exploring FMT as a therapeutic approach. However, there are inherent factors presenting as obstacles for the use of FMT in these patients. In this review paper, we discussed the principles and biologic effects of FMT, examined the factors rendering patients with hematologic and oncologic conditions to increased risks for relapsed/refractory CDI, explored ongoing FMT studies, and proposed novel uses for FMT in these groups of patients. Finally, we also addressed the challenges of applying FMT to these groups of patients and proposed ways to overcome these challenges.

show abstract

Rifaximin on intestinally‐related pathologic changes in sickle cell disease

Cited by 14 publications

References 10 publications

Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions

Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions

Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events

Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice

Contact Info

Product

Resources

About